Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low on Thursday. The company traded as low as GBX 34 and last traded at GBX 38, with a volume of 36127 shares changing hands. The stock had previously closed at GBX 36.50.
Faron Pharmaceuticals Oy Stock Performance
The stock has a market capitalization of £77.09 million, a P/E ratio of -3.30 and a beta of 1.12. The company has a quick ratio of 1.09, a current ratio of 2.40 and a debt-to-equity ratio of 154.15. The company has a 50-day moving average price of GBX 38.76 and a two-hundred day moving average price of GBX 41.77.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Read More
- Five stocks we like better than Faron Pharmaceuticals Oy
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
